Market open

Blueprint Medicines/BPMC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Ticker

BPMC
Trading on

Industry

Biotechnology

Employees

638

BPMC Metrics

BasicAdvanced
$5.5B
Market cap
-
P/E ratio
-$3.34
EPS
0.63
Beta
-
Dividend rate
$5.5B
0.63
$121.90
$43.89
615K
3.706
3.481
195.381
231.185
-7.97%
-19.26%
-65.09%
14.744
17.15
17.15
-15.389
60.80%
-63.80%
-24.05%
-16.85%

What the Analysts think about BPMC

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Blueprint Medicines stock.

BPMC Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BPMC Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy BPMC

$

Sign up or log in to buy
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Blueprint Medicines stock?

Blueprint Medicines (BPMC) has a market cap of $5.5B as of October 11, 2024.

What is the P/E ratio for Blueprint Medicines stock?

The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of October 11, 2024.

Does Blueprint Medicines stock pay dividends?

No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of October 11, 2024.

When is the next Blueprint Medicines dividend payment date?

Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.

What is the beta indicator for Blueprint Medicines?

Blueprint Medicines (BPMC) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.